WO2003092606A3 - Cholinesterase inhibitors to prevent injuries caused by chemicals - Google Patents

Cholinesterase inhibitors to prevent injuries caused by chemicals Download PDF

Info

Publication number
WO2003092606A3
WO2003092606A3 PCT/US2003/013575 US0313575W WO03092606A3 WO 2003092606 A3 WO2003092606 A3 WO 2003092606A3 US 0313575 W US0313575 W US 0313575W WO 03092606 A3 WO03092606 A3 WO 03092606A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemicals
injuries caused
cholinesterase inhibitors
prevent injuries
cholinesterase inhibitor
Prior art date
Application number
PCT/US2003/013575
Other languages
French (fr)
Other versions
WO2003092606A2 (en
Inventor
John Ieni
Raymond Pratt
Original Assignee
Eisai Co Ltd
John Ieni
Raymond Pratt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, John Ieni, Raymond Pratt filed Critical Eisai Co Ltd
Priority to GB0424188A priority Critical patent/GB2405336A/en
Priority to AU2003228796A priority patent/AU2003228796A1/en
Publication of WO2003092606A2 publication Critical patent/WO2003092606A2/en
Publication of WO2003092606A3 publication Critical patent/WO2003092606A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Abstract

The invention provides methods for treating and preventing injuries caused by chemicals by administering to a patient a therapeutically effective amount of at least one cholinesterase inhibitor. The chemicals can be, for example, agricultural compounds or chemical weapons. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof.
PCT/US2003/013575 2002-05-01 2003-05-01 Cholinesterase inhibitors to prevent injuries caused by chemicals WO2003092606A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0424188A GB2405336A (en) 2002-05-01 2003-05-01 Cholinesterase inhibitors to prevent injuries caused by chemicals
AU2003228796A AU2003228796A1 (en) 2002-05-01 2003-05-01 Cholinesterase inhibitors to prevent injuries caused by chemicals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656002P 2002-05-01 2002-05-01
US60/376,560 2002-05-01

Publications (2)

Publication Number Publication Date
WO2003092606A2 WO2003092606A2 (en) 2003-11-13
WO2003092606A3 true WO2003092606A3 (en) 2004-01-08

Family

ID=29401361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013575 WO2003092606A2 (en) 2002-05-01 2003-05-01 Cholinesterase inhibitors to prevent injuries caused by chemicals

Country Status (3)

Country Link
AU (1) AU2003228796A1 (en)
GB (1) GB2405336A (en)
WO (1) WO2003092606A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403775B2 (en) 2003-04-24 2016-08-02 Incyte Corporation AZA spiro alkane derivatives as inhibitors of metalloproteases

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2275670T3 (en) 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. NEW METHODS USING CHOLESTERASE INHIBITORS.
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
US7888346B2 (en) * 2004-09-24 2011-02-15 Universtiy of Maryland, Baltimore Method of treating organophosphorous poisoning
AU2012200612B2 (en) * 2004-09-24 2014-11-20 The Government Of The United States, As Represented By The Secretary Of The Army Method of treating organophosphorus poisoning
US9132135B2 (en) 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
JP4872044B2 (en) * 2005-09-30 2012-02-08 財団法人ヒューマンサイエンス振興財団 Cardiac remodeling inhibitor and heart failure treatment
KR20100017766A (en) 2007-05-10 2010-02-16 에이엠알 테크놀로지, 인크. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
ES2700541T3 (en) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, its preparation and use
ES2705247T3 (en) 2013-03-14 2019-03-22 Univ Columbia 4-phenylpiperidines, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
CA2947174C (en) 2014-04-30 2023-02-28 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
AR103297A1 (en) 2014-12-30 2017-05-03 Forma Therapeutics Inc PIRROLO AND PIRAZOLOPIRIMIDINAS AS INHIBITORS OF THE SPECIFIC PROTEASE 7 OF UBIQUITINA
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
JP2018504430A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939095A (en) * 1993-12-10 1999-08-17 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
US6114347A (en) * 1993-12-10 2000-09-05 Lts Lohmann Therapie-Systeme Gmbh Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors
US6264974B1 (en) * 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939095A (en) * 1993-12-10 1999-08-17 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
US6114347A (en) * 1993-12-10 2000-09-05 Lts Lohmann Therapie-Systeme Gmbh Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors
US6264974B1 (en) * 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403775B2 (en) 2003-04-24 2016-08-02 Incyte Corporation AZA spiro alkane derivatives as inhibitors of metalloproteases

Also Published As

Publication number Publication date
AU2003228796A8 (en) 2003-11-17
AU2003228796A1 (en) 2003-11-17
WO2003092606A2 (en) 2003-11-13
GB2405336A (en) 2005-03-02
GB0424188D0 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2004108157A3 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
PT1509232E (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease
MXPA04009352A (en) COMBINATION THERAPY FOR THE TREATMENT OF PARKINSONaCOES DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S).
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
WO2005023179A3 (en) Combination methods of treating cancer
DK1121111T3 (en) Compounds for the treatment of weight loss
DK1216038T3 (en) Use of inhibitors of the renin angiotensin system in the prevention of cardiovascular events
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
MXPA05003104A (en) N-substituted hydromorphones and the use thereof.
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
CA2383785A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2002034201A3 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
WO2005037347A3 (en) Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
AU7040201A (en) A new use for deferiprone
WO2006031706A3 (en) Betulinol derivatives as anti-hiv agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 0424188

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20030501

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP